1 February 2022 in Journal of Controlled Release
24 March 2021 in Advanced Healthcare Materials
4 November 2025 in Orthopaedic Proceedings
Aim: To investigate the targeted and systemic in vivo pharmacokinetics of gentamicin and clindamycin released from a carbohydrate-ester based dual antibiotic (gentamicin/clindamycin) sustained-release depot formulation (CC-G/C). Method: 2.5 mL of CC-G/C comprising clindamycin and gentamicin was injected via 21G needles into a ~1 cm³ bone void in the proximal tibias and the adjacent soft tissue of pigs. Following bilateral injection, microdialysis was employed in two pigs to sample the concentrations of gentamicin and clindamycin from the adjacent soft tissues over 12 hours (n=4). Simultaneous plasma samples were obtained as a reference (n=2). Samples from bone, tissue, plasma and CC-G/C depots were collected from pigs on days 1, 3, and 7 (n=3 pigs per timepoint). Antibiotic concentrations in bone, tissue and plasma were quantified by LC-MS/MS and depots by LC-UVvis/ELSD. Results: Microdialysis indicated high and consistent soft tissue levels (> 300±100 µg/mL clindamycin and > 70±30 µg/mL gentamicin) for both antibiotics during the initial 12 hours, with minimal systemic spillover (< 0.07±0.02 µg/mL). On day 1, average tissue concentrations of gentamicin and clindamycin reached 700±200 µg/g and 3700±700 µg/g in trabecular bone, respectively, and 400±100 µg/g and 1900±500 µg/g in bone void. Over the 7-day study period, levels of both antibiotics in bone declined, with half-lives of 2.6 days for clindamycin and 1.9 days for gentamicin, effectively reaching 80±20 µg/g and 700±100 µg/g at day 7. For the void, levels remained high (>300µg/mg) throughout the study. The on- to off-target ratio (AUC tissue /AUC plasma ) was 3000 for gentamicin and 100,000 for clindamycin. Analysis of recovered CC-G/C depots demonstrated an accumulated release of both gentamicin and clindamycin of 27-46 % of the entire depot on day 1 and 58-82% on day 7. Conclusion: CC-G/C facilitates high and sustained in vivo concentrations of gentamicin and clindamycin in trabecular bone and bone voids for up to the 7 days investigated, with minimal systemic exposure. These findings support the potential of CC-G/C as a promising carbohydrate-ester based drug delivery technology for managing orthopedic infections by achieving local antibiotic levels sufficient to eradicate bacterial biofilms and persister cells.
8 May 2026 in Journal of Bone and Joint Infection
Introduction: Achieving sustained local antibiotic concentrations is critical for managing orthopedic infections. This proof-of-concept study evaluated release kinetics, local/systemic concentrations, and histological responses to CarboCell G/C, an injectable gentamicin- and clindamycin-eluting depot in a porcine bone void model. Methods: CarboCell G/C containing 111 mg g−1 gentamicin-docusate and 70 mg g−1 clindamycin was injected into and around a tibial bone void in 11 pigs. Antibiotic concentrations in target tissues and systemic spillover were measured at 1–12 h by microdialysis and liquid chromatography coupled to tandem mass spectrometry (LC-MS/MS) and in tissue homogenates at 1, 3, and 7 d. Release was quantified by high-performance liquid chromatography (HPLC), and tolerability was assessed histologically. Results: Microdialysis showed high stable antibiotic tissue levels during the first 12 h with minimal systemic spillover. Peak gentamicin and clindamycin concentrations in bone were 730 ± 170 and 3700 ± 700 µg g−1 and 42 ± 15 and 360 ± 120 µg g−1 in soft tissue, respectively. Tissue half-lives ranged from 43–62 h for clindamycin and 40–46 h for gentamicin. Recovered depots had released ∼ 30 %–50 % of their antibiotic content at day 1 and ∼ 60 %–80 % by day 7. Depots elicited a mild–moderate local inflammatory response. Conclusion: CarboCell G/C provides sustained high local antibiotics for at least 7 d with minimal systemic spillover, supporting further evaluation in orthopedic infection management.
21 October 2026 in Physica Medica
This study compared a liquid to solid fiducial markers regarding visibility, artifact characteristics on X-ray imaging and dose perturbation for image-guided proton therapy (IGPT) of abdominal tumors. Additionally, the radio-opaque composition of the liquid fiducial marker was optimized, and the chemical stability after proton beam irradiation was analyzed. The fiducial markers inserted into an anthropomorphic abdominal phantom were exposed to X-ray, single-energy computed tomography (SECT), dual-energy CT (DECT) and cone-beam CT (CBCT) to determine contrast-to-noise ratios (CNR) and artifacts. Proton dose perturbation estimations were performed using a Monte Carlo dose algorithm. Chemical stability following proton beam irradiation was assessed with biophysical and optical methods. The CNR of the liquid marker with a volume ≥ 100 μl (CNR ≤ 2.69) on 2D X-ray images was superior to the solid markers (CNR ≤ 1.72). The artifact areas (A) and severity in the CT modalities were more pronounced for the solid (e.g. A ≤ 279.4 mm3) than for the liquid fiducial marker (A ≤ 30.5 mm3). Dose mitigation of ≥ 50% in a proton beam was calculated for solid fiducial markers, while the liquid marker less influenced the dose distribution. Increasing radio-opaque content in the liquid prototypes improved visibility (CNR ≤ 2.97) without significantly increasing artifact volume (SECT: A ≤ 40.5 mm3) or dose perturbation. No degradation of the liquid fiducial marker's chemical composition was observed. The liquid fiducial marker demonstrated comparable visibility and chemical stability with reduced artifact generation and dose perturbation compared to solid markers, indicating superiority for IGPT of abdominal tumors. Optimization of the liquid marker composition may be considered.